Emergent BioSolutions (EBS) Misses Q1 EPS by 65c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.11 -2.07%
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
NVNO, BOTJ, XOM, More
Revenue Growth %: +32.0%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
NVNO, BOTJ, XOM, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.21, $0.65 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $156.1 million versus the consensus estimate of $205 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies has trade finance-related exposure of $300M to Radiant World - Reuters
- Bank of the James (BOTJ) Tops Q2 EPS by 71c
- RBC Capital on Palantir (PLTR): 'Valuation remains unattractive'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
